FDA Drug Application (202212) for NEVIRAPINE by CIPLA LIMITED

Back to FDA Applications sponsored by CIPLA LIMITED

Application Number202212
Product Number001
FormTABLET, FOR SUSPENSION; ORAL
Dosage50MG
Product Market Status Tentative Approval
Therapeutic Equivalence Evaluation Code
Reference Drug
Drug NameNEVIRAPINE
Active IngredientNEVIRAPINE

Active IngredientCount
List of drugs with Active Ingredient NEVIRAPINE17


Back to FDA Applications sponsored by CIPLA LIMITED